Three antibiotics in just over a week have impressed in Phase III trials, with Tetraphase, The Medicines Company and Paratek all confident of being on the market in the next year
The clinical success of antibiotics this summer is continuing apace with Tetraphase Pharmaceuticals Inc. the latest firm in the field to present positive late-stage results.
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
The US FDA approved Blujepa for the treatment of uncomplicated urinary tract infections, marking the first new mechanism of action for the infection in more than 30 years.
Professor Anil Koul shares vignettes of his life and career trajectory, a captivating mix of hope, science and destiny that took him to the lab of eminent cancer biologist Alex Ullrich at the Max Planck Institute and also saw him contribute to the development of breakthrough TB drug bedaquiline. He also talks about Medicine 3.0 and the intersection of science and spirituality.
The company is developing doravirine and islatravir together as an alternative to therapies containing integrase inhibitors, like Biktarvy, especially as HIV patients age.
The two companies were among those presenting data at CROI that highlighted the next frontiers of competition in the HIV space.
The agency loosened requirements for echocardiograms and removed contraindications for a number of commonly used drugs.
The IL-4/IL-13 inhibitor has been approved in the US as the first targeted therapy in over a decade for chronic itching.
The company announced positive topline results for the oral GLP-1 drug in type 2 diabetes that beat expectations.
